Telehealth Informed Consent

Telehealth allows a licensed clinician to evaluate and communicate with you remotely using electronic systems. Care may include review of an intake, secure messages, audio, video, and electronic prescribing when permitted and clinically appropriate.

• More convenient access to a licensed clinician.
• Reduced travel and faster exchange of information.
• Ongoing communication through designated secure systems.

• A remote evaluation may not provide all information available during an in-person examination.
• Technology can fail, delay communication, or present privacy risks.
• A clinician may require laboratory work, records, or in-person evaluation before making a decision.
• A medication may be inappropriate, ineffective, or cause side effects.

You agree to provide complete and accurate health information, disclose all medications and conditions, follow clinical instructions, use medications only as prescribed, and promptly report adverse effects or material changes. You must be physically located in an eligible state at the time of care.

You may ask questions and may withdraw consent to telehealth before or during care, subject to services already provided and legal recordkeeping duties. Declining telehealth may require seeking in-person care elsewhere.

Telehealth records may become part of your medical record. Clinical communications should occur only through the designated secure system. Privacy protections and permitted disclosures are governed by applicable law and the clinical provider's policies.

Telehealth through this service is not for emergencies. Call 911 or go to the nearest emergency department for severe symptoms, a suspected allergic reaction, thoughts of self-harm, or any urgent medical concern.

You agree to verify your identity and confirm your physical location at the time of each consultation. Care is provided only by clinicians licensed in that state. Services are not available in California or outside the United States.

GLP-1 medications such as semaglutide and tirzepatide carry an FDA boxed warning about the risk of thyroid C-cell tumors and must not be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Other risks include pancreatitis, gallbladder disease, low blood sugar, kidney problems, serious allergic reactions, and gastrointestinal side effects. These medications should not be used during pregnancy. Your clinician will review risks, benefits, and alternatives with you.